Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Women's Studies |
| Therapuetic Areas: | Reproductive |
| Healthy: | No |
| Age Range: | 18 - 40 |
| Updated: | 2/2/2019 |
| Start Date: | March 2016 |
| End Date: | July 2019 |
To assess potential benefits associated with both intermittent (use for 3 weeks, remove for 1
week, as defined in the package insert) and continuous (use for 4 weeks, then replace) CVR
use among women either with BV or at high risk for BV. The investigators will also recruit
women who are HSV2-infected.
week, as defined in the package insert) and continuous (use for 4 weeks, then replace) CVR
use among women either with BV or at high risk for BV. The investigators will also recruit
women who are HSV2-infected.
Inclusion Criteria:
- ≥18-40 year old women
- BV+ by Amsel criteria and Nugent score OR history of BV in the prior 6 months
- Willing to use the NuvaRing as directed
- Not intending or wishing to become pregnant over the course of the study
- Capable of providing written informed consent
Exclusion Criteria:
- Current pregnancy
- Desire/intent to become pregnant over the course of the study
- Women who are less than 6 weeks postpartum
- Contraindications to hormonal contraceptive use per package insert, including history
of deep vein thrombosis, smoking in women older than 35 years
- Current IUD
- Unable to comprehend consent material because of language barrier or psychological
difficulty
We found this trial at
1
site
Click here to add this to my saved trials
